GHRP-2: Growth Hormone Releasing Peptide-2 Research Profile

What Is GHRP-2?

GHRP-2, also known by its research name pralmorelin, is a synthetic hexapeptide growth hormone secretagogue. Its amino acid sequence is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Developed in the 1990s as part of an extensive effort to create synthetic compounds capable of stimulating endogenous growth hormone (GH) release, GHRP-2 emerged as one of the most potent members of the growth hormone-releasing peptide family. It belongs to the second generation of GHRPs, representing an optimization over earlier compounds like GHRP-6 in terms of GH-releasing potency, though not necessarily in terms of selectivity.

GHRP-2 has attracted considerable research interest both as a tool for studying the somatotropic axis and as a potential diagnostic agent. In some countries, it has been approved under the name pralmorelin for use in evaluating growth hormone deficiency, where its reliable and robust stimulation of GH release serves as a provocative test of pituitary function.

Mechanism of Action

GHRP-2 exerts its primary effects by binding to the growth hormone secretagogue receptor type 1a (GHS-R1a), the endogenous target of the hunger hormone ghrelin. This receptor is a G-protein coupled receptor expressed on somatotroph cells in the anterior pituitary gland, as well as in the hypothalamus and various peripheral tissues.

Intracellular Signaling

Upon binding to GHS-R1a, GHRP-2 activates a phospholipase C (PLC)-dependent signaling cascade. This leads to the generation of inositol triphosphate (IP3), which triggers the release of calcium from intracellular stores. The resulting increase in cytoplasmic calcium promotes the exocytosis of GH-containing secretory granules from somatotroph cells. This calcium-dependent signaling pathway is fundamentally different from the cyclic AMP (cAMP)/protein kinase A (PKA) pathway activated by growth hormone-releasing hormone (GHRH), which is why combining a GHRP with a GHRH analog can produce synergistic GH release.

Hypothalamic Actions

Beyond its direct pituitary effects, GHRP-2 also acts at the hypothalamic level. Research indicates that GHS-R1a activation in the hypothalamus can stimulate the release of endogenous GHRH and may partially suppress somatostatin release. These central actions amplify the GH-releasing effect beyond what would be expected from pituitary stimulation alone, and they contribute to the compound's potency.

Effects on Other Hormones

A defining characteristic of GHRP-2 is its broader hormonal footprint compared to more selective GHRPs like Ipamorelin. Published research has documented the following additional hormonal effects:

• Cortisol: GHRP-2 produces a mild to moderate increase in cortisol levels, mediated through activation of hypothalamic pathways. This effect is dose-dependent and generally less pronounced than that observed with Hexarelin, but it is a consistent finding in clinical studies.
• Prolactin: Similarly, GHRP-2 has been shown to elevate prolactin levels at GH-stimulating doses. The magnitude of prolactin elevation is typically modest but statistically significant in controlled studies.
• ACTH: Some studies have reported increases in adrenocorticotropic hormone (ACTH) alongside cortisol elevation, suggesting hypothalamic-pituitary-adrenal (HPA) axis engagement.
• Appetite stimulation: Through ghrelin receptor activation in the hypothalamus, GHRP-2 produces an increase in appetite, though this effect is less intense than that associated with GHRP-6.

Key Properties

Property	Detail
Chemical Name	Pralmorelin / GHRP-2
Sequence	D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular Weight	~817.9 Da
Peptide Length	6 amino acids (hexapeptide)
Primary Target	GHS-R1a (ghrelin receptor)
GH Release Potency	High (among the most potent GHRPs)
Cortisol Effect	Mild to moderate increase
Prolactin Effect	Mild to moderate increase
Appetite Stimulation	Moderate
Half-Life	Approximately 15-30 minutes
Administration	Subcutaneous injection (research settings)

Research Landscape

Diagnostic Applications

One of the most established research applications for GHRP-2 is as a provocative agent in the diagnosis of growth hormone deficiency (GHD). The rationale is straightforward: because GHRP-2 reliably stimulates GH release in individuals with intact pituitary function, a blunted response to GHRP-2 administration can indicate impaired somatotroph reserve. In Japan, pralmorelin received regulatory approval for this diagnostic application, and it has been used in clinical settings to assess GH secretory capacity.

Studies evaluating GHRP-2 as a diagnostic tool have generally reported good sensitivity and specificity for distinguishing GH-deficient from GH-sufficient individuals, particularly when appropriate cutoff values are used for peak GH response.

GH Axis Physiology Studies

GHRP-2 has served as an important research tool for studying the regulation of GH secretion. By comparing responses to GHRP-2 alone, GHRH alone, and the combination of both, researchers have been able to characterize the degree of synergy between the ghrelin and GHRH pathways. These studies have demonstrated that co-administration of GHRP-2 and GHRH produces GH release that substantially exceeds the sum of individual responses, confirming the independent but complementary nature of these two stimulatory pathways.

Age-Related GH Decline

Research has examined how the GH response to GHRP-2 changes with aging. Studies have shown that while older adults generally produce a lower absolute GH response to GHRP-2 compared to younger adults, the relative stimulatory effect is preserved, suggesting that the somatotroph cells retain their capacity to respond to ghrelin receptor activation even as overall GH secretion declines with age.

Obesity and Metabolic Research

The relationship between GHRP-2, the ghrelin system, and metabolic parameters has been an active area of investigation. Research has explored how obesity affects the GH response to GHRP-2, with findings generally indicating that obesity attenuates the response. The appetite-stimulating properties of GHRP-2 have also been studied in the context of conditions involving impaired appetite, though the clinical development of these applications remains limited.

Safety Profile

The safety data on GHRP-2 comes primarily from diagnostic studies and short-term research protocols. This information is presented for educational purposes only and does not constitute medical advice.

• Hormonal effects: The elevation of cortisol and prolactin observed with GHRP-2 raises theoretical concerns about long-term use, though the magnitude of these effects is generally modest in acute settings.
• Appetite changes: The appetite-stimulating effect, while potentially beneficial in some contexts, could be problematic in others. This effect appears to be mediated through hypothalamic ghrelin receptor activation.
• Injection site reactions: As with most subcutaneously administered peptides, local injection site reactions have been reported, typically described as mild and transient.
• Desensitization: Some research suggests that repeated GHRP-2 administration may lead to a degree of receptor desensitization over time, though this appears less pronounced than with Hexarelin.
• Long-term safety: Comprehensive long-term safety data for GHRP-2 is limited, as most published studies involve acute or short-duration protocols.

It is important to note that GHRP-2 is not approved as a therapeutic agent in most jurisdictions. Its regulatory status varies by country, and it is primarily available as a research compound.

Comparison With Other GHRPs

Property	GHRP-2	GHRP-6	Ipamorelin	Hexarelin
GH Release Potency	High	Moderate-High	Moderate	Highest
Cortisol Elevation	Mild-Moderate	Mild	Minimal	Moderate-Significant
Prolactin Elevation	Mild-Moderate	Mild	Minimal	Moderate-Significant
Appetite Stimulation	Moderate	Strong	Minimal	Mild-Moderate
Selectivity	Moderate	Low-Moderate	High	Low
Desensitization Risk	Moderate	Moderate	Low	High

GHRP-2 occupies a middle ground among GHRPs: it is more potent than GHRP-6 for GH release, more selective than Hexarelin, but less selective than Ipamorelin. This intermediate profile means that researchers must weigh the benefit of higher GH-releasing potency against the broader hormonal effects when selecting a GHRP for experimental protocols.

Current Status

GHRP-2 remains an active area of research, though its clinical development path has been limited compared to some other GH secretagogues. As pralmorelin, it has found a niche application in GHD diagnostics. In the broader research community, it continues to serve as an important pharmacological tool for studying ghrelin receptor function and GH axis regulation.

For a comprehensive overview of how GH secretagogues work together, including the synergy between GHRH analogs and GHRPs, see CJC-1295 and Ipamorelin: The Research Behind Growth Hormone Peptides. For a broader guide to the secretagogue class, visit Growth Hormone Secretagogues: Complete Guide.

This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any decisions related to peptides or other compounds.